Embryonic Plant Stem Cell Researcher Dominique Richard Awaits Two Pending Patents
Researcher and author Dominique Richard, who is affiliated with PSC Distribution LLC (www.epsce.com) announced earlier this week that two potentially groundbreaking biological drugs patents are nearing approval.
New York, NY – Researcher and author Dominique Richard, who is affiliated with PSC Distribution LLC (www.epsce.com), announced earlier this week that two potentially groundbreaking biological drugs patents are nearing approval. Richard is also close to completing a 4,500- page medical encyclopedia that he’s been cataloging for more than a decade. Indeed, 2013 is shaping up to be a busy year for the man many in the alternative medicine arena refer to as the “grandfather of Embryonic Phytochemistry and Plant Stem Cell research.”
Richard’s first pending patent, in the field of dentistry, is a drug delivery system with embryonic plant extracts that uses dental trays for chronic biofilm periodontal infections. While the timetable is not yet certain, Richard anticipates patent approval in the first or second quarter of 2013.
His second patent, in the field of disease protocols, involves a process for the innovative engineering of an embryonic phytochemistry protocol for diseases where no treatment currently exists (or where the existing treatment is limited in terms of its effectiveness). This protocol will involve the use of endophytic plants – embryonic phytochemicals with broad-spectrum antibiotics biological activities to be delivered intravenously. FDA human trials are expected to be initiated in 2013 for biological-drug application.
“It’s difficult to overstate the impact these could have on modern medicine,” Richard says of his two pending patents. Indeed, the American public’s perception of the pharmaceutical industry is extremely negative right now, as we are inundated with commercials for synthetic drugs whose potential side effects seem to far outweigh the medical problems the drugs are supposed to be helping. “Here we have two completely natural approaches to very real medical problems. These patents could be the catalyst to change the way the medical community views disease.”
Richard certainly has the experience required of someone making such a bold statement. He has spent nearly 40 years studying and researching embryonic photochemistry, blood chemistry, hematology, flow cytometry- immunotherapy and neurotransmitters – blood platelet catecholamines and many others. He enjoys an international reputation as the foremost authority on embryonic phytochemistry and embryonic phytohormones, eclectic phytopharmacology, nutrition sciences, synthetic pharmacology and every other type of modality.
He keeps researching and discovering all sorts of new novel biological protocols in trying to relieve the many whom suffer from poor health. He claims that we are getting poisoned at an alarming rate levels where the capacity of the liver can no longer detoxifies effectively the body burden is greater than what the capacity is. You don’t have to wonder if this is the true look around so many sick people like no time in history
It remains to be seen whether Richard’s patents and biological drug engineering designs will begin a chain of events that indeed changes modern medicine, but one thing is certain: he isn’t stopping. As soon as he puts the finishing touches on that medical encyclopedia, Richard plans to return to teaching and mentoring because his true ambition is one of altruism: he simply want to help people feel better – it just so happens that his vehicle for making a difference in people’s lives is embryonic phytochemistry, phytopharmacology, phytopharmacokinetics and medicine. He keeps studying for the last 35 years every specialty in medicine and he is only interested in proving nature’s superiority chemistry and effectiveness. He is determined to prove that in nature are the answers for most illnesses if we only took the time to study its enormous chemistry.
- Contact Information
- Niocla Dinatale
- Marketing Manager
- PSC Distribution LLC
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.